Actinium Pharmaceuticals to Participate in American Society for Blood and Marrow Transplantation 2017 Corporate Council Meeting
- Actinium is now a member of the ASBMT™ Corporate Council
- Two day event focused on facilitating dialogue aimed at advancing the field of bone marrow transplantation and cellular therapy
NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options announced today that the Company has recently joined the American Society for Blood and Marrow Transplantation (ASBMT™) Corporate Council and that representatives from the Company will attend the 2017 Corporate Council retreat being held September 24 - 25, 2017 in Amelia Island, Florida.
Dr. Mark Berger, Actinium’s Chief Medical Officer said, “Actinium is excited to be part of ASBMT’s corporate council. ASBMT has a long-standing commitment to improving the field of bone marrow transplant, which is in alignment with Actinium’s vision of expanding access to this important field of medicine through the development of our novel drug candidates, particularly Iomab-B. I am very much looking forward to attending this meeting and having valuable discussions with leaders in the bone marrow transplant field regarding our drug candidates and their potential for improving bone marrow transplant outcomes.”
About the American Society for Blood and Marrow Transplantation
The American Society for Blood and Marrow Transplantation is an international professional membership association of more than 2,200 physicians, investigators and other health care professionals from more than 45 countries. ASBMT strives to be the leading organization promoting research, education and clinical practice in the field of blood and marrow transplantation and related cellular therapy.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options. Actinium's proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. The Company's lead product candidate Iomab-B is designed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant (“BMT”). BMT is often the only potential cure for patients with blood-borne cancers but current standard preparation for a transplant requires chemotherapy and/or total body irradiation that result in significant toxicities. Iomab-B aims to enable a faster and less toxic preparation of patients seeking BMT, potentially leading to increased transplant success and survival rates. The Company is currently conducting a single pivotal 150-patient, multicenter Phase 3 clinical study of Iomab-B in patients with relapsed or refractory acute myeloid leukemia (“AML”) age 55 and older. The Company's second product candidate, Actimab-A, is currently in a multicenter open-label, 53-patient Phase 2 trial for patients newly diagnosed with AML age 60 and over. Actimab-A is being developed to induce remissions in elderly patients with AML who lack effective treatment options and often cannot tolerate the toxicities of standard frontline therapies. In addition, Actinium is developing Actimab-M, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial. Actinium is also utilizing its alpha-particle technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors. More information available at www.actiniumpharma.com and Twitter feed @ActiniumPharma, www.twitter.com/actiniumpharma.
Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Actinium Pharmaceuticals, Inc.
Vice President, Finance and Corporate Development
Marek Ciszewski, J.D.
Released September 20, 2017